Intermittent zoledronic acid prevents bone loss in adults after allogeneic hematopoietic cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 9, 2013, Pages 1361-1367

  Hari, Parameswaran ^a   DeFor, Todd E ^b   Vesole, David H ^c   Bredeson, Christopher N ^d   Burns, Linda J ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Allogeneic hematopoietic cell; Bisphosphonates; Osteoporosis; Transplantation; Zoledronic acid

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BUSULFAN; CALCIUM CARBONATE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OSTEOCALCIN; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VITAMIN D; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE DENSITY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG FATALITY; EPISTAXIS; FEMALE; FEMUR NECK; FOLLOW UP; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; MALE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONMYELOABLATIVE CONDITIONING; OSTEOLYSIS; OSTEOPENIA; PNEUMONIA; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; SEPSIS; SMALL LYMPHOCYTIC LEUKEMIA; SURVIVAL; WHOLE BODY RADIATION; ADULT; AGED; ALLOTRANSPLANTATION; CLINICAL TRIAL; DRUG EFFECTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PREVENTION AND CONTROL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; DIPHOSPHONATES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84882740395     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.06.015     Document Type: Article

References (36)

1. Tauchmanova L., Colao A., Lombardi G., et al. Bone loss and its management in long-term survivors from allogeneic stem cell transplantation. JClin Endocrinol Metab 2007, 92:4536-4545.
2. Yao S., McCarthy P.L., Dunford L.M., et al. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. Bone Marrow Transplant 2008, 41:393-398.
3. Yao S., Smiley S.L., West K., et al. Accelerated bone mineral density loss occurs with similar incidence and severity, but with different risk factors, after autologous versus allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010, 16:1130-1137.
4. Ebeling P.R., Thomas D.M., Erbas B., et al. Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation. JBone Miner Res 1999, 14:342-350.
5. Weilbaecher K.N. Mechanisms of osteoporosis after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2000, 6:165-174.
6. Stern J.M., Sullivan K.M., Ott S.M., et al. Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study. Biol Blood Marrow Transplant 2001, 7:257-264.
7. Kananen K., Volin L., Tahtela R., et al. Recovery of bone mass andnormalization of bone turnover in long-term survivors of allogeneic bone marrow transplantation. Bone Marrow Transplant 2002, 29:33-39.
8. Kashyap A., Kandeel F., Yamauchi D., et al. Effects of allogeneic bone marrow transplantation on recipient bone mineral density: A prospective study. Biol Blood Marrow Transplant 2000, 6:344-351.
9. Schulte C., Beelen D.W., Schaefer U.W., Mann K. Bone loss in long-term survivors after transplantation of hematopoietic stem cells: a prospective study. Osteoporos Int 2000, 11:344-353.
10. Gandhi M.K., Lekamwasam S., Inman I., et al. Significant and persistent loss of bone mineral density in the femoral neck after haematopoietic stem cell transplantation: long-term follow-up of a prospective study. Br J Haematol 2003, 121:462-468.
11. Massenkeil G., Fiene C., Rosen O., et al. Loss of bone mass and vitamin D deficiency after hematopoietic stem cell transplantation: standard prophylactic measures fail to prevent osteoporosis. Leukemia 2001, 15:1701-1705.
12. Valimaki M.J., Kinnunen K., Volin L., et al. Aprospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin. Bone Marrow Transplant 1999, 23:355-361.
13. Tauchmanova L., De Simone G., Musella T., et al. Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation. Bone Marrow Transplant 2006, 37:81-88.
14. Tauchmanova L., Ricci P., Serio B., et al. Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation. JClin Endocrinol Metab 2005, 90:627-634.
15. Tauchmanova L., Selleri C., Esposito M., et al. Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies. Osteoporos Int 2003, 14:1013-1019.
16. Chae Y.S., Kim J.G., Moon J.H., et al. Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients. Bone Marrow Transplant 2009, 44:35-41.
17. Grigg A.P., Shuttleworth P., Reynolds J., et al. Pamidronate reduces bone loss after allogeneic stem cell transplantation. JClin Endocrinol Metab 2006, 91:3835-3843.
18. D'Souza A.B., Grigg A.P., Szer J., Ebeling P.R. Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation. Intern Med J 2006, 36:600-603.
19. Kananen K., Volin L., Laitinen K., et al. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. JClin Endocrinol Metab 2005, 90:3877-3885.
20. Li E.C., Davis L.E. Zoledronic acid: a new parenteral bisphosphonate. Clin Ther 2003, 25:2669-2708.
21. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. NEngl J Med 2007, 356:1809-1822.
22. McClung M., Miller P., Recknor C., et al. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol 2009, 114:999-1007.
23. Woo S.B., Hellstein J.W., Kalmar J.R. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006, 144:753-761.
24. Kintzel P.E. Anticancer drug-induced kidney disorders. Drug Saf 2001, 24:19-38.
25. Skerjanec A., Berenson J., Hsu C., et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. JClin Pharmacol 2003, 43:154-162.
26. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
27. Snedecor G, Cochran W. Statistical Methods (eighth ed.), Iowa.1989.
28. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. JAm Stat Assoc 1958, 53:457-481.
29. Lin D.Y. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med 1997, 16:901-910.
30. Carpenter P.A., Hoffmeister P., Chesnut C.H., et al. Bisphosphonate therapy for reduced bone mineral density in children with chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007, 13:683-690.
31. Ganguly S., Divine C.L., Ajitawi O.S. Prophylactic use of zoledronic acid to prevent early bone loss is safe and feasible in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. Clin Transplant 2012, 26:447-453.
32. Banfi A., Podesta M., Fazzuoli L., et al. High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: a mechanism for post-bone marrow transplantation osteopenia. Cancer 2001, 92:2419-2428.
33. Lee W.Y., Cho S.W., Oh E.S., et al. The effect of bone marrow transplantation on the osteoblastic differentiation of human bone marrow stromal cells. JClin Endocrinol Metab 2002, 87:329-335.
34. Tauchmanova L., Serio B., Del Puente A., et al. Long-lasting bone damage detected by dual-energy x-ray absorptiometry, phalangeal osteosonogrammetry, and invitro growth of marrow stromal cells after allogeneic stem cell transplantation. JClin Endocrinol Metab 2002, 87:5058-5065.
35. Sorror M.L., Sandmaier B.M., Storer B.E., et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 2011, 306:1874-1883.
36. Sorror M.L., Storer B., Storb R.F. Validation of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in single and multiple institutions: limitations and inferences. Biol Blood Marrow Transplant 2009, 15:757-758.